Rev. OFIL 2017, 27;2:193-199
Fecha de recepción: 14/05/2016 – Fecha de aceptación: 11/01/2017
González García J1, Madueño Alonso A2, Gutiérrez Nicolás F1, Nazco Casariego GJ1, Valcárcel Nazco C3, González de la Fuente GA1, García Gil S1
1 Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias (España)
2 Servicio de Microbiología y Medicina Preventiva. Complejo Hospitalario Universitario de Canarias (España)
3 Fundación Canaria de Investigación Sanitaria (FUNCANIS) (España)
Jonathan González García
Complejo Hospitalario Universitario de Canarias
Carretera Ofra, s/n
Correo electrónico: firstname.lastname@example.org
Background: Ceftaroline was non-inferior to vancomycin/aztreonam with respect to clinical cure rates in the treatment of complicated skin and skin structure infections (cSSSIs) in two Phase III trials, however was associated with significantly better clinical response to 72h.
Purpose: To evaluate the cost-effectiveness of ceftaroline fosamil vs. vancomycin and aztreonam in MRSA-confirmed cSSSIs using a decision analytic (DA) model.
Methods: A DA model was developed from the perspective of Spanish Health System to assess the cost-effectiveness of ceftaroline compared with the combination vancomycin-aztreonam. The effectiveness of the treatments were estimated from clinical response to 72h based from the retrospective analysis of pooled from two Phase III randomized controlled trials (CANVAS 1 and CANVAS 2). Univariate sensitivity analyses tested the robustness of the model to determine the degree to wich model uncertainties influenced outcomes.
Results: The rate of clinical response at 72h, was 74% for the ceftaroline group and 66.2% for vancomycin-aztreonam group (difference, 7.8%; 95% CI, 1.3 to 14.0 p=0.018). The total (medical plus drug) costs were € 7,917 for ceftaroline and € 8,210 for vancomycin-aztreona. In all of one-way sensitivity analysis scenarios, ceftaroline fosamil was the cost-effective treatment option.
Conclusion: Ceftaroline is cost-effective in patients with cSSSIs versus vancomycin-aztreonam.
Key Words: Ceftaroline, cost-effectiveness, complicated skin and skin structure infections, Staphylococcus aureus, economic evaluation.